

# + Strategic responses to advanced burn management


Smith+Nephew provides an evidence-based approach to providing care for burn patients



## + The impact of burns<sup>1</sup>

# 486,000

Nearly half a million people receive medical treatment for burns each year.<sup>100</sup>



## 40,000

people are hospitalized for burn-related injuries<sup>101</sup>



## 3,275

deaths from fires or smoke inhalation<sup>102-103</sup>




## 2:41

is the average amount of time that passes between each civilian death by fire<sup>102-103</sup>

 = 3,275 people

# The barriers to burn healing



## Necrotic tissue

Necrotic tissue provides a food source for a variety of bacteria progressing quickly to infection if not managed appropriately<sup>2-3</sup>




## Visibility

The extent of damage may not be visually apparent at initial assessment<sup>1,4</sup>



## Delayed treatment

Presence of eschar can delay a clinician's decision to take the patient to the OR for surgical debridement and grafting<sup>1,4</sup>




## Patient pain

Burns are a very painful form of trauma because of the multitude of pain receptors and nerves throughout the skin<sup>1</sup>

**Smith+Nephew aims to reduce the costs associated with burn care, both patient and economic**

**TIME is of the essence.** Immediate treatment of burns is vital to advance healing.<sup>1-4</sup>




Tissue non-viable  
or deficient<sup>5-6</sup>



Infection or  
inflammation<sup>5-6</sup>



Moisture  
imbalance<sup>5-6</sup>



Epithelial edge  
advancement<sup>5-6</sup>

# Our Advanced Burn Management Portfolio


Designed around the T.I.M.E. principles to promote wound healing

## T

**Tissue non-viable or deficient**




Collagenase  
SANTYL<sup>®</sup> Ointment  
250 units/g




VERSAJET<sup>®</sup> II  
Hydrosurgery System

## I

**Infection or inflammation**



ACTICOAT<sup>®</sup> Antimicrobial  
Barrier Dressings



ALLEVYN<sup>®</sup> Ag

## M

**Moisture imbalance**




ALLEVYN LIFE  
Foam Dressings



EXU-DRY<sup>®</sup>  
Anti-Shear  
Wound Dressing



SOLOSITE<sup>®</sup>  
Gel and Dressing



INTRASITE<sup>®</sup>  
GEL

## E


**Epithelial edge advancement**



PICO<sup>®</sup> Single  
Use Negative  
Pressure Wound  
Therapy System



RENASYS<sup>®</sup> TOUCH  
Negative Pressure  
Wound Therapy  
System



OASIS<sup>®</sup> Matrix  
Products

## Other products for burn management



CICA-CARE<sup>®</sup>  
Silicone Gel Sheet



CUTICERIN<sup>®</sup>  
Gauze Dressing



CONFORMANT<sup>®</sup> 2  
Non-Adherent  
Contact Layer



DURAMAX<sup>®</sup> S  
Silicone Super  
Absorbent Dressing

# TIME

## Tissue non-viable or deficient

Although autolytic debridement occurs naturally, assisted debridement may help to accelerate the wound healing process.<sup>5</sup>



VERSAJET<sup>®</sup>  
HydroSurgery System



Collagenase SANTYL<sup>®</sup>  
Ointment 250 units/g

**The presence of eschar in a burn wound** can delay critical treatment decisions, such as surgical debridement or grafting<sup>1,4</sup>



## + VERSAJET HydroSurgery System Optimized hydroSurgical debridement device

Our **VERSAJET HydroSurgery System** offers unmatched precision and control through the use of a high-pressure stream of saline to optimize surgical debridement and provide the patients and your facility with important benefits. It is intended for wound debridement, including burns.

### Key benefits

- Enables precise selection, excision and evacuation of non-viable tissue, bacteria and contaminants using a tissue-sparing technique<sup>7</sup>
- Helps to preserve viable tissue and reduce the number of debridement procedures<sup>7-8</sup>
- VERSAJET System creates a smooth wound bed for improved synthetic and graft placements
- Removes bacteria, which can help to reduce the risk of infection<sup>7-8</sup>
- Can help to reduce the number of debridements required to prepare the wound bed for closure, which may shorten hospital stay<sup>9-10</sup>
- Decreases readmissions resulting from surgical site infections (SSIs)

# Collagenase SANTYL<sup>◇</sup> Ointment (250 units/g)

Cleaves collagen at seven sites and creates bioactive byproducts<sup>104, 105</sup>

The depth of a burn is not static. Unlike other traumatic wounds, the extent of injury in burn wounds – especially those of partial thickness — develops in a complex and multifaceted way.<sup>129-131</sup>

In the treatment of appropriate burns, SANTYL Ointment:

- Can be applied immediately after initial burn stabilization treatment without harming healthy tissue<sup>106, 107</sup>
- May be a safe and effective debridement agent for burn wounds with respect to decreasing wound healing time and minimizing pain without increasing the risk of infection<sup>11</sup>
- Changes the burn microenvironment via its enzymatic mechanism of action to fight inflammation and stimulate the migration and proliferation of fibroblasts, keratinocytes, and endothelial cells<sup>104, 105, 108</sup>
- May promote visualization of the extent of the burn and assist in determining the need for excision or grafting<sup>109</sup>
- Potentially saves OR costs and time<sup>109</sup>

## Clostridium Collagenase Impact on Zone of Stasis Stabilization and Transition to Healthy Tissue in Burns<sup>109, 132</sup>

### Study design

- **Animal study design:** Classic burn comb model (porcine)
- **Products:** Clostridium Collagenase (0.8% w/w) suspended in hydrogel vs. hydrogel control
- **Objective:** Evaluation of clostridium collagenase's ability to effectively minimize burn progression
- **Methods:** Clostridium collagenase or control vehicle daily and biopsied at various time points. Biopsies were evaluated for factors associated with progressing necrosis as well as inflammatory response associated with treatment

### Study results

Debridement with collagenase stabilized the zone of stasis and limited burn conversion by:

- Digesting devitalized collagen
- Resolving inflammation
- Maintaining vascular networks


You can wait for the burn to declare itself or you can help it decide.<sup>132</sup>




**T I M E**

## Infection or inflammation

To manage infection, treatment of burns should be based on making the burnt area unfavorable for the growth and multiplication of organisms<sup>3</sup>



ACTICOAT<sup>®</sup> Dressings



ALLEVYN<sup>®</sup> Ag

**Burn wounds can rapidly become colonized** by a variety of pathogens progressing quickly to infection if not managed appropriately<sup>2-3</sup>

## ACTICOAT<sup>®</sup> Antimicrobial Barrier Dressings

Act with certainty by choosing ACTICOAT Dressings for reliable efficacy

### Fast acting

ACTICOAT Dressings can kill bacteria as quickly as 30 minutes (in vitro)<sup>18, 19, 118, 119</sup>

In a clinical trial including chronic and post-traumatic wounds:

- ACTICOAT Dressing was shown in a study to eliminate all signs and symptoms of infection in 60% of wounds within two weeks<sup>120</sup>

### Broad efficacy<sup>121</sup>

Effective against Gram positive and Gram negative bacteria, yeast and fungi inc. antibiotic resistant organisms such as MRSA, VRE, Enterobacteriaceae strains containing ND M-1 carbapenemases

In a clinical trial including chronic and post-traumatic wounds:

- Patients treated with ACTICOAT Dressings were nearly three times more likely to heal during the 8-week study than patients treated with other silver dressings<sup>120</sup>

### Sustained action

With a sustained action of :

- Up to seven days for ACTICOAT 7 and ACTICOAT Flex 7 Antimicrobial Dressing<sup>34, 122-124</sup>
- Up to 3 days for ACTICOAT and ACTICOAT Flex 3 Antimicrobial Dressing<sup>125-127</sup>

From a patient perspective:


- Fewer dressing changes reduce stress and trauma. Limiting disturbance to the wound can also lead to faster healing<sup>128</sup>



# ACTICOAT<sup>®</sup> is clinically proven as an effective option for burn patients




protects the wound site from bacterial contamination<sup>21-25</sup>



helps to manage existing infection<sup>26</sup>



is less painful during wear and removal<sup>21,27</sup>



is fast acting<sup>26,28-29</sup>



is cost effective<sup>22-23,25,28</sup>

ACTICOAT is not intended to provide sole treatment for infected wounds. It may be used on infected wounds which are being managed per local clinical protocol. ACTICOAT is not indicated for use on third-degree burns.

## + ACTICOAT Flex 3 and Flex 7

Highly conformable dressings that can help manage infection for up to 7 days<sup>30\*</sup>

- Flexible, low adherent polyester layer coated with Nanocrystalline Silver
- Conforms to the body to maintain contact with the wound surface
- Low adherent properties help minimize wound trauma at dressing changes<sup>31-32</sup>
- Provides effective antimicrobial barrier properties for up to 3 days<sup>33</sup> (ACTICOAT Flex 3) or 7 days<sup>30</sup> (ACTICOAT Flex 7) against a broad spectrum of wound pathogens, including MRSA (in vitro)<sup>17-20</sup>
- Can be used with negative pressure wound therapy (NPWT) for up to 3 days




\*Depending on the dressing used.

## + ACTICOAT<sup>®</sup>

Three-layer dressing that can help manage infection for up to 3 days<sup>34</sup>


- One inner rayon/polyethylene absorbent core layer between two layers of Nanocrystalline Silver coated mesh
- Antimicrobial activity remains effective for up to 3 days<sup>34</sup>
- Can be used on wounds that warrant or that need frequent dressing changes (e.g., burns)



## + ACTICOAT 7

Five-layer dressing that can help manage infection for up to 7 days<sup>35-36</sup>

- Two inner rayon/polyethylene absorbent core layers between three layers of Nanocrystalline Silver coated mesh
- Antimicrobial activity remains effective for up to 7 days<sup>35-36</sup>
- Can be used on wounds that warrant or that need frequent dressing changes (e.g., burns)



# ALLEVYN<sup>®</sup> Ag Antimicrobial Foam Dressing

Non-Adhesive | Gentle Border | Adhesive

## Exceptional fluid management, powered by silver

Wound infection can significantly compromise patient wellbeing and place heavy burdens on healthcare economies. The ALLEVYN Ag dressings have been designed to combine the essential qualities of the ALLEVYN range with the added antimicrobial activity of silver.

- Unique tri-layer construction enables optimal fluid handling to support moist wound healing<sup>37</sup>
- Dressing provides an effective barrier to bacteria<sup>38-40</sup>
- Comfortable for patients, conforms to body contours, and easy to apply and remove<sup>41-44</sup>





# T I M E

## Moisture imbalance


An appropriate burn dressing can remove copious amounts of exudate while retaining a moist environment that can accelerate burn closure.<sup>5</sup>



ALLEVYN<sup>®</sup> LIFE  
Foam Dressings




INTRASITE<sup>®</sup> GEL



SOLOSITE<sup>®</sup>  
Gel and Dressing



EXU-DRY<sup>®</sup>  
Anti-Shear Wound Dressing



**Breathable:** Film layer provides a bacterial barrier

**Innovative:** EXUMASK<sup>®</sup> Change Indicator helps patients and carers own the recovery process while providing high patient satisfaction through fewer dressing changes.

**Hyper-absorbant:** Lock-away core helps minimize leakage of fluid

**Protective:** Hydrocellular foam cushions, absorbs exudate

**Gentle and Secure:** Silicone adhesive wound contact layer can be repositioned and may reduce trauma to the wound during dressing changes

## + ALLEVYN LIFE Foam Dressings

An all-in-one option for pressure injury prevention and treatment as part of your burn strategy

ALLEVYN LIFE is an anatomically shaped, multi-layered foam dressing designed to help manage wound exudate and to help prevent pressure injuries in patients who are immobile because of burns.


- Provides optimal moist wound environment for moderately and highly exuding wounds<sup>49-50</sup>
- Less leakage occurs due to the lock-away, hyper-absorbent layer and wider border<sup>50-51</sup>
- Masking layer reduces the visibility of exudate thereby helping to reduce the frequency of dressing changes<sup>52</sup>
- Up to 7 day wear time, for locations except the sacral area<sup>51,53</sup>
- Unique change indicator provides visual indication that dressing should be changed<sup>52</sup>

# Use of **ALLEVYN<sup>®</sup> LIFE Foam Dressings** can help decrease resource utilization

nearly  
**2x longer**  
lasting than other dressings<sup>54</sup>

**71% reduction**  
in hospital acquired pressure injuries (HAPIs),  
and works with a variety of medical devices<sup>110</sup>

**ALLEVYN and ALLEVYN LIFE** products come in a variety of shapes and sizes to help manage pressure injury prevention on burns



### **ALLEVYN LIFE**

An all-in-one dressing for pressure injury prevention as part of a comprehensive prevention protocol



### **ALLEVYN LIFE Sacrum**

Designed specifically to help prevent sacral pressure injuries as part of a comprehensive prevention protocol



### **ALLEVYN LIFE Heel**

Helps in the prevention of pressure injuries on heels as part of a comprehensive prevention protocol



### **ALLEVYN Gentle Border**

Versatile silicone adhesive and ability to cut



### **ALLEVYN Adhesive**

Secure adhesive for highly active mobile patients



### **ALLEVYN Gentle**

Low tack adhesive for fragile skin



### **ALLEVYN Gentle Border Lite**

Versatile silicone adhesive low levels of exudate



### **ALLEVYN Ag**

Effective (in vitro) against a broad spectrum of bacteria



### **ALLEVYN Non-Adhesive**

Non-adhesive for fragile skin

## INTRASITE<sup>◇</sup> GEL Hydrogel Wound Dressing

A powerful hydrogel that debrides necrotic wounds in non-immunocompromised patients by rehydrating devitalized tissue<sup>55-58</sup>

**INTRASITE GEL** is clinically proven to address the necrotic burden in chronic wounds. It encourages autolytic debridement and desloughing in non-immunocompromised patients while caring for delicate granulation tissue and surrounding skin.<sup>55-57</sup>

- Facilitates re-epithelialization and leads to reduced scarring<sup>57-58</sup>
- Effective desloughing through rehydration and absorption<sup>55-57</sup>
- Allows for rapid granulation and re-epithelialization<sup>57,59-60</sup>
- Unique cross-linked polymer with propylene glycol
- Easy to apply and remove; produces no pain on application and minimal pain during treatment<sup>57,61-63</sup>



## SOLOSITE<sup>◇</sup> Wound Gel

Designed to create the moist wound environment

**SOLOSITE Wound Gel** is a hydrogel based wound dressing with preservatives that assists in the autolytic debridement of necrotic tissue. It can donate moisture to rehydrate non-viable tissue and absorb exudate while retaining its structure in the wound.<sup>68-69</sup>

- Absorbs exudate while retaining structure in the wound<sup>68-69</sup>
- Easy to apply and remove<sup>70</sup>
- Donates moisture to rehydrate non-viable tissue
- Contains water-swallowable polymer that absorbs exudate yet remains gel-like until saturated
- Non-sensitizing<sup>71</sup> and non-irritating<sup>72</sup>



Note: Autolytic debridement is not recommended or sufficient in immunocompromised patients.<sup>64-67</sup>



## + EXU-DRY<sup>o</sup> Specialty Absorptive Wound Dressing

An extra level of comfort for patients

EXU-DRY Anti-Shear Absorbent Dressing's unique multi-layered construction delivers four layers in a single dressing, which provides extra absorbent comfort for patients and may help reduce nursing time.<sup>73</sup>

- Non-adherent wound contact layer may reduce patient pain during dressing changes<sup>73-75</sup>
- Anti-shear layer reduces friction and shearing during patient movement<sup>75-77</sup>
- Has been shown in specific case studies to reduce time for dressing changes in comparison to foams and gauzes<sup>73,75</sup>
- Semi-permeable non-occlusive outer layer allows for vapor and moisture exchange
- Soft and pliable, which ensures effective, intimate contact with the wound

**EXU-DRY is available in a wide range of sizes and shapes to accommodate virtually any wound or body contour.**

# T I M E

## Epithelial edge advancement

Cell proliferation and repair of the [extracellular] matrix is a key stage of the wound healing process.<sup>5</sup>



PICO<sup>®</sup> Single Use Negative Pressure Wound Therapy System



RENASYS<sup>®</sup> TOUCH Negative Pressure Wound Therapy System



OASIS<sup>®</sup> Matrix Products System

Wounds with a dysfunctional or missing extracellular matrix (ECM) cannot support proper wound closure<sup>78</sup>

## + PICO Single Use Negative Pressure Wound Therapy (NPWT) System

### Fewer complications + More convenience

PICO is a single use NPWT system that features a canister-free design<sup>79</sup>, which can enhance patient portability. It is indicated for use on acute wounds, chronic wounds, closed surgical incisions, and partial thickness burns. It can be worn up to 7 or 14 days, depending on exudate level.



Can help improve patient experience<sup>80-81</sup>



Simple application and operation



Enhanced portability




Powered canister-free NPWT



Can be cost effective<sup>83</sup>



Clinically effective<sup>81-82</sup>



### High moisture transmission rate

to transpire as much as 80% of the wound fluid<sup>82</sup>

### Silicone adhesive layer

protects the wound environment and helps to minimize trauma and pain on removal<sup>51,86</sup>

### Super absorbent core

locks fluid away from wound<sup>84-85</sup>



# RENASYS<sup>®</sup> TOUCH Negative Pressure Wound Therapy System

A streamlined NPWT solution for complex wounds

RENASYS Touch is designed to simplify NPWT for challenging wounds.


- Enables same-day discharge\*
- Soft port technology reduces the need for bridging, potentially cutting application time by an estimated 50%.<sup>116</sup>
- Utilizes initiative touchscreen
- Clinically comparable to V.A.C.<sup>™</sup>,<sup>117</sup>

\*Through our distribution partnership with Rotech Healthcare



## When should you use PICO<sup>®</sup> sNPWT or RENASYS tNPWT?


Amount of drainage  
What is level of exudate?



Wound size  
Will it fit under PICO dressing?



Filler and tunneling  
Does PICO dressing conform to the wound bed?





## OASIS® Wound Matrix

Offering flexibility and versatility for a wide array of wounds

**OASIS Matrix Products** are derived from porcine small intestinal submucosa (SIS),<sup>87</sup> which provides a bioresorbable, structural, functional, complex, and dynamic scaffold to help the body replace or repair damaged or dysfunctional extracellular matrices (ECM).

- Versatile and affordable for routine use
- Provides pathways for cellular migration and vascular ingrowth<sup>114-115\*</sup>
- Proprietary process to retain multiple ECM components and proteins found in the human dermis
- Porcine SIS is the most studied scientific platform for advanced wound therapies, with more than 1,600 publications about the technology, 600+ publications on different clinical applications, and 5 published clinical studies in wound care<sup>88</sup>
- Available in a range of sizes covering up to 600cm<sup>2</sup>

*Simple to store. Simple to handle. Simple to manage.*



### Efficacious

- Ten OASIS Matrix RCTs demonstrate improved wound closure



### Experience of care

- Available off-the-shelf and stored at room temperature
- Can be used with physician's preferred closure technique



### Economical

- Low cost per cm<sup>2</sup> (89)

**Contraindications for OASIS Matrix Products:** This device is derived from a porcine source and should not be used in patients with known sensitivity to porcine material. This device is not indicated for use in third-degree burns. For detailed product information, including indications for use, contraindications, precautions and warnings, please consult the product's Instructions for Use (IFU) prior to use.

## + Use of OASIS® Matrix Products on burns showed:


**Good aesthetic outcomes** with no complications or infections<sup>111-113</sup>

**Closure in 100%** of second-degree burns in 7-14 days in two studies<sup>112-113</sup>

**Less scarring** and more mature epidermis than silver-containing hydrofiber dressing in one study<sup>111</sup>

**Earlier granulation tissue** and more mature epidermis when compared to Suprathel® in one study<sup>113</sup>

**No need for** painful daily dressing changes<sup>113</sup>







## CICA-CARE<sup>◊</sup> Silicone Gel Sheet

A soft, naturally self-adhesive, occlusive silicone sheet that is flexible and durable

- Made from medical grade silicone, reinforced with a silicone membrane backing
- Self-adhesive contact side can be placed on a scar while thin silicone backing support does not adhere to clothing<sup>90-92</sup>
- Durable silicone membrane<sup>90-92</sup> is less likely to crumble compared to other silicone gel sheets<sup>93-94</sup>
- Flexible and conformable to various anatomical locations<sup>90, 92, 95</sup>
- Washable and re-usable for up to 28 days<sup>90, 92, 95</sup>
- Demonstrated to be effective in the management of scars up to 30 years old<sup>96-97</sup>
- Designed for management of both existing and new hypertrophic and keloid scars and as a prophylactic therapy on closed wounds to help prevent hypertrophic and keloid scarring<sup>90, 98</sup> which could occur in burn patients



## CUTICERIN<sup>◊</sup> Low Adherent Tulle Gras Dressing

An all-purpose, low-adherent, impregnated gauze dressing

- Made of smooth acetate fabric with a defined mesh size, and a hydrophobic coating which is based on petrolatum, paraffin and wool wax alcohol<sup>99</sup>
- Dressing impregnated with CUTICERIN Ointment<sup>99</sup>
- Low adherent nature, which helps dressing lift off easily without trauma or pain<sup>99</sup>
- Allows air and exudate to pass freely through the dressing<sup>99</sup>
- Indicated for superficial, exudating wounds such as burns, abrasions, split-thickness skin graft donor sites and radiation injuries<sup>99</sup>

## CONFORMANT<sup>◇</sup> 2 Non-Adherent Contact Layer

A sterile, air-permeable, transparent, polyethylene wound-contact layer designed to act as a non-adherent interface between the wound and the secondary dressing

- Sterile and air-permeable<sup>100</sup>
- Non-adherent<sup>100</sup>
- Indicated to provide covering for the wound bed<sup>100</sup>
- May be used in the management of partial- and full-thickness wounds including leg ulcers, pressure ulcers, second-degree burns, surgical wounds and diabetic foot ulcers<sup>100</sup>
- For OTC applications, CONFORMANT 2 is indicated for the management of minor wounds, including abrasions, skin tears, first- and second-degree burns and scalds<sup>100</sup>



## DURAMAX<sup>◇</sup> S Silicone Super Absorbent Dressing


Super absorbent micro-adhesive silicone dressing for management of highly exudating wounds

- Minimize the risk of maceration to the wound and surrounding tissue
- Up to 7-day wear time
- Self-adhesive, can be applied without secondary dressing
- Easy to apply and remove
- DURAMAX S can absorb and retain fluid while under standard 40mmHg of compression



## + Your partner in advanced burn management

Smith+Nephew offers a comprehensive portfolio that helps manage wound healing during every stage of recovery — designed around the T.I.M.E. principles.



**Our team of clinical support specialists** will help you establish protocols and implement practices that facilitate burn care treatment in your facility.

**Our post-acute team** will help ensure that proper burn care for your patients continues after discharge.

**Our collaborative sales representative** will help you maintain an appropriate supply of all of the products you need.



Find a full list of our **product SKUs** at the end of this document

**Important Safety Information**

Indications: Collagenase SANTYL Ointment ("SANTYL") is indicated for debriding chronic dermal ulcers and severely burned areas. Contraindications: SANTYL is contraindicated in patients who have shown local or systemic hypersensitivity to collagenase. Warnings and Precautions: The optimal pH range of collagenase is 6 to 8. Higher or lower pH conditions will decrease the enzyme's activity and appropriate precautions should be taken. The enzymatic activity is also adversely affected by certain detergents, and heavy metal ions such as mercury and silver which are used in some antiseptics. As such, the wound should be properly cleansed prior to application of SANTYL. Debilitated patients should be closely monitored for systemic bacterial infections because of the theoretical possibility that debriding enzymes may increase the risk of bacteremia. A slight transient erythema has been noted occasionally in the surrounding tissue, particularly when SANTYL was not confined to the wound. Adverse Reactions: No allergic sensitivity or toxic reactions have been noted in clinical use when used as directed. The risk information provided herein is not comprehensive. To see the complete Prescribing Information, please see the FDA-approved product labeling, here: <https://www.santyl.com/pdf/SANTYL-PI.pdf>. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or call 1-800-FDA-1088.

Contraindications for OASIS Matrix Products: This device is derived from a porcine source and should not be used in patients with known sensitivity to porcine material. This device is not indicated for use in third-degree burns. For detailed product information, including indications for use, contraindications, precautions and warnings, please consult the product's Instructions for Use (IFU) prior to use.

**References**

1. Church, et al. Burn Wound Infections, 2006, Clin. Microbiol. Rev. 403-434. 2. Evers LH et al. 120101 Exp Dermatol; 17: 777-783. 3. Wallace AB. 119511 The exposure and treatment of burns. Lancet 1166531: 501-4. 4. Jackson, D. M. The diagnosis of the depth of burning. Br J Surg., 1953. 5. Schultz GS, Sibbald RG, Falanga V, et al. Wound bed preparation: a systematic approach to wound management. Wound Repair Regen. 2003; 11 (Suppl 1):S1-S28. 6. Leaper DJ, Schultz G, Carville K, et al. Extending the TIME concept: what have we learned in the past 10 years? Int Wound J. 2012; 9 (Suppl 2): 1-19. 7. Granick MS, et al. Efficacy and cost – effectiveness of a high-powered parallel waterjet for wound debridement. Wound Repair Regen. 2006;14:394-397. 8. Granick M, et al. Toward a common language: surgical wound bed preparation and debridement. Wound Repair Regen. 2006;14:S1-S10. 9. Cubison TC, et al. Dermal preservation using the VERSAJET Hydrosurgery system for debridement of paediatric burns. Burns. 2006;32:714-720. 10. Mosti G, et al. The debridement of chronic leg ulcers by means of a new, fluidjet-based device. Wounds. 2006;18:227-237. 11. Pham CH, Collier ZJ, Fang M, Howell A, Gillenwater TJ. The role of collagenase ointment in acute burns: a systematic review and meta-analysis. Journal of Wound Care. 2019 Feb 1:28(Sup2):S9-15. 12. SANTYL Ointment Prescribing Information, 13. Wound Healing in Partial-Thickness Burn Wounds Treated With Collagenase Ointment Versus Silver Sulfadiazine Cream. Hensbrough, Jet al. Burn Care & Rehabilitation. Vol. 16, No. 3, Part 1. May/June 1995. 14. Gaw (2007) Ref: 0708058 An in-vitro Assessment of the Bacterial Log Reduction Properties Induced by Silver Containing ACTICOAT Post-op Dressings. 15. Demonstrable. 16. Woodmansey et al. Poster presentation SAWC 2006 San Antonio. 17. Westaim (Sherritt) (2001) report ref 93/001. Broad spectrum efficacy. 18. Wright JB et al. (1998) American Journal of Infection Control, 26(6): 572-577. 19. Wright JB et al. (1999) Am J Infect Control ;27:344-350. 20. Yin HQ et al. J (1999) Burn Care Rehabil; 20:195-200. 21. Tredget et al (1998) . Journal of Burn Care and Rehabilitation; 19(6): 531-537. 22. Fong (2005) Burns 31,562- 567. 23. Tonkin and Wood. (2005) Primary Intention; 13(4): 163-168. 24. Muangman P et al.(2006) Journal of The Medical Association of Thailand. 89(7): 953-8. 25. Peters D, Vercherre C. (2006) Journal of Burn Care and Research; 27(2):198-201. 26. Huang Y et al. (2007) Burns; 33(2):161-6. 27. Varas RP et al. (2005) Journal of Burn Care and Rehabilitation; 26(4): 344-347. 28. Cuttie L et al. (2007) Burns; 33 701-707. 29. Demling, R and DeSanti, (2002) M. Burns; 28(3): 264-6. 30. Daubney L, Silver release testing of ACTICOAT Flex 7 Dressings. Report ref DS/08/062/R2. 31. Walton G: Wound Healing Study Summary Report. 32. Myers D: ACTICOAT Dressing: Wound bed prep and wound trauma. 33. Daubney L. Silver release testing of ACTICOAT Flex 3 Dressings. Report ref DS/08/078/R2. 34. Westaim Report ref #971030 The Antimicrobial Activity of Westaim's Acticoat Silver Coated Dressing against Clinically Relevant Organisms over an Extended Period of time. 35. Westaim Report Ref #001213 Long Term Comparative Evaluation of Silverlon and ACTICOAT 7 Dressings against MRSA. 36. Westaim Report Ref #010322 Seven day efficacy of ACTICOAT 7 Dressings against multiple organisms. 37. The clinical and physical properties of ALLEVYN Ag dressings and the moist wound environment. 38. Smith & Nephew Wound Management, report ref: 070305, Bacterial Barrier testing (wet-wet) on samples of ALLEVYN Gentle, ALLEVYN Gentle Border dressings with 7 day test duration against S. marcescens. Vaughan J October 2010. 39. Smith & Nephew Data on File Report 070304 – Bacterial Barrier Testing (wet-wet) on samples of ALLEVYN Ag Non-Adhesive dressing with a 7 day test duration against MRSA, E. Woodmansey, March 2007. 40. Data on File 0703013 – Bacterial Barrier testing (wet-wet) on samples of ALLEVYN Ag adhesive dressing with a 7 day test duration against MRSA, E. Woodmansey, Feb 2007. 41. Harding KG, Bale S. A randomised clinical study to evaluate and compare the performance of ALLEVYN Adhesive and Tielle dressings in the management of exuding wounds in the community; Smith & Nephew healthcare. 42. Managing diabetic foot lesions with ALLEVYN Heel dressing , Watret L (2000) The Diabetic Foot, 3(1),21-22. 43. Data on file report ref: 0711086 – Results from a 7 day volunteer trial evaluating ALLEVYN Gentle dressings in terms of pain on removal, dressing retention and other physical characteristics. A. Bond December 2007. 44. Smith & Nephew Medical Ltd. Report Ref: HVT050 Results from an open, prospective, randomised, within volunteer comparison of Dakota and Mepilex Border, Palmer S., & Smith G. 4th December 2008. 45. Rossington A. Product performance of the next generation ALLEVYN LIFE. Data on File report GMCA-DOF/08-April 2016. 46. Daubney L. Physical testing ALLEVYN LIFE Gen2. Data on File Report DS/15/025/R- May 2016. 47. E. Mumbly. Subjective comparison of masking ability of ALLEVYN LIFE Gen2. Data on File Report DS/16/061R.- Feb 2016. 48. Earl K. Wound model testing of ALLEVYN LIFE Gen2 using horse serum. Data on File Report DS/14/303/R.- April 2016. 49. Data on File Ref DS/09/013/R2. ALLEVYN Gentle Border Dressing Physical Properties. Daubney L, May 2009. 50. Myers D. The clinical and physical properties of ALLEVYN Gentle Border dressing and the moist wound environment. November 2007. 51. Hurd T et al. A multicentre in-market evaluation of ALLEVYN Gentle Border. Wounds UK, 2009, Vol 5, No3. 52. Data on File Report DS.12.124. DOF. Fluid Handling Properties of ALLEVYN LIFE. 53. Volunteer Trial Report Reference VTR/HVT 050. Results from an open, prospective, randomised, within volunteer comparison of Dakota and Mepilex Border. Palmer S and Smith G. December 2008. 54. Joy H et al. A collaborative project to enhance efficiency through dressing change practice. Journal of Wound Care. Vol 24, No 7. July 2015 P3-4 16. 55. Colin, D; Kurring, P; Quinlan, D; Yvon, C. The clinical investigation of an amorphous hydrogel compared with a dextranomer paste dressing in the management of sloughy pressure ulcers. Proceedings of the 5th European conference on advances in wound management, Harrogate, UK, November 1995. 56. Flanagan, M. The efficacy of a hydrogel in the treatment of wounds with Non-viable tissue. Journal of wound care. 1995 Vol 4(6), 264-267. 57. Regan, M: The use of INTRASITE Gel in healing open sternal wounds. Ostomy/Wound management, Journal for Extended Patient Care Management, Volume 38, No. 3, April 1992. 58. Thomas, S; Rowe, HN; et al: A new approach to the management of extravasation injury in neonates. The Pharmaceutical Journal (1987) Nov: 584 - 585. 59. Young T, Williams C, Benbow M et al. A study of two hydrogels used in the management of pressure sores. 103-106. 60. Milward P, Boucher-Payne S. Amputation or plastic surgery? The conservation management of an extensively ulcerated leg: a case study in the home care environment. [Poster] 1992. 61. Westerhof, W; Mekkes, JR: A pilot study comparing INTRASITE Gel with saline soaked gauze for debridement, Ref CTR90/08 by D Myers. 62. Todd, M: The use of an amorphous hydrogel in the management of granulating wounds. Poster at Woundcare Society Meeting, Harrogate, UK, November 1994. 63. Ricci E, Cassino R, Secreti P. Treatment of necrotic tissue with INTRASITE gel. 64. Ayello EA, Cuddigan JE. Debridement: Controlling the necrotic/cellular burden. Adv in Skin and Wound Care 2004;17:66-75. 65. Eming, S. A., T. Kriep, and J. M. Davidson. 2007. Inflammation in wound repair: molecular and cellular mechanisms. J. Invest. Dermatol. 127: 514– 525. 66. Lucas, T. et al., Differential Roles of Macrophages in Diverse Phases of Skin Repair, The Journal of Immunology, 2010, 184: 3964–3977. 67. John Rabbia PT, DMT, MS, GCS, CWS, in Geriatric Physical Therapy (Third Edition), 2012 68. SOLOSITE Gel Premarked Notification Submission K932263. 69. SOLOSITE Gel Formulation (F-44), 70. Demonstrable. 71. Delayed Contact Sensitization Study (A Maximum method) In the Guinea Pig, Report # 92T-18386-00, NAMSA. 72. Primary Skin Irritation Test (FHSA) in the Rabbit, Report # 92T-18386-00, NAMSA. 73. Lorenzini et al. An open evaluation of a new dressing for the burn wound. Smith & Nephew poster presentation. 74. Hemphill V, et al. Clinical Evaluation of EXU-DRY Burn/Trauma Dressings pg 25-44. BayState Medical Center, Springfield, MA pg 12-24. 75. Edwards, J (2001) Use of Exu-Dry in the management of a variety of exuding wounds. British Journal of Nursing, 2001 Vol 10, No 12. 76. Brown-Etris M, Smith JA, Pasceri P et al (1994) Case studies: considering dressing options. Ostomy/Wound Management 40(5): 46-52. 77. Bolinger B (1995) Burn care in the home. J Wound Contention Nurs 22(3): 122-7. 78. Badylak SF. Semin Cell Dev Biol. 2002;13(5):377-383. 79. DS/11/037/R2 In vitro wound model testing of PICO at a moderate exudate flow rate. 80. Hurd T, et al. Use of a portable, single-use negative pressure wound therapy device in home care patients with low to moderately exuding wounds: a case series. Ostomy Wound Management. 2014; 60(3):30-6. 81. Karlakki, S., Brem, M., Giannini, S., Khanduja, V., Stannard, J., and Martin, R. Negative pressure wound therapy for surgical incision management in orthopedic surgery. BJR. 2013. 82. Malmjsjo, M; Huddleston, E; Martin, R; Biological Effects of a Disposable, Canisterless Negative Pressure Wound Therapy System; Eplasty 2014. 83. Delhougne G, Hogan C, Tarka K, Nair S. A Retrospective, Costminimization Analysis of Disposable and Traditional Negative Pressure Wound Therapy Medicare Paid Claims. Ostomy Wound Manage. 2018;64(1):26-33. 84. Data on file reference DS/11/037/R2 – In vitro wound model testing of PICO™ at a moderate exudate flow rate; Sarah Roberts, March 2011. 85. Data on file reference DS/11/057/R2 – In vitro wound model testing if PICO at a low exudate flow rate; Sarah Roberts, April 2011. 86. Data on file reference 1102010 - Bacterial Barrier Testing (wet-wet) of PICO dressing with a 7 day Test Duration against S.marcescens; Helen Lumb, February 2011 (in-vitro). 87. Data on file. In vivo data. Cook Biotech, Inc. 88. Data on file. Cook Biotech, Inc. 89. Mihalich-Levin L, Cohen A, Wetzel S. Association of American Medical Colleges (AAMC) Presentation. December 2, 2014. 90. Carney et al (1994) CICA-CARE Gel sheeting in the management of hypertrophic scarring. Burns, 20 (2, 163-167). 91. Donald (1994) Comparison of 2 types of silicone gel sheets. ANZBA bulletin 16 (10-11). Held by the Regulatory Affairs Department. 92. Stability Study QA3324, CICA-CARE Dressings – Results of 12 Weeks Stability Testing, 29 March 1994. 93. Posluszyns JA Jr, Conrad P, Halerz M, Shankar R, Gamelli RL. Surgical burn wound infections and their clinical implications. J Burn Care Res. 2011;32(2):324–333. 94. Wound management worldwide, forecast to 2024. MedMarket Diligence Web site. <http://blog.mediligence.com/2015/11/30/woundmanagementworldwide-forecast-to-2024>. Accessed April 19, 2016. 95. Wash/Wear QA/3298, CICA-CARE Adhesive Elastomer Sheet – Simulated Use/Wash Trial Study dated 2nd March 1994. 96. Quinn et al (1985). Non-pressure treatment of hypertrophic scars. Burns (1985), 12, 102-108. 97. Quinn, Karen J. (1987), Silicone Gel in scar treatment. Burns (Supplement), 13, S33-S40. 98. Mercer, N.S.G (1989), Silicone Gel in the treatment of keloid scars. British Journal of Plastic Surgery 42 (1), 83-87. 99. Extracted from CUTICERIN Instructions For Use (IFU), 100. CONFORMANT 2 Instructions For Use. 100. National Hospital Ambulatory Medical Care Survey: 2011 Emergency Department Summary Tables (accessed on 28/12/2015, at HYPERLINK "[https://nam11.safelinks.protection.outlook.com?url=http%3A%2F%2Fwww.cdc.gov%2Fncchs%2Fahcd%2Fweb\\_tables.htm%2F232011&data=05%7C01%7CJessica.Avery%40smith-nephew.com%7C8ad0d87740af49a0dae308db5b07e4fd%7C273106dc287842ebb7c8069df334687%7C0%7C0%7C638203861705955737%7CUknown%7CTWFPbGzsb3d8eyJWJoiMC4wLjAwMDAilCJlQioiV2luMzIlCJBTi6Ik1haWwWILCJXVCi6Mn0%3D%7C3000%7C%7C%7C%7C&sdata=tEro56wHrxo9677yqSMLo9mVpX99qUBuBcdNSxqWwggw%3D&reserved=0](https://nam11.safelinks.protection.outlook.com?url=http%3A%2F%2Fwww.cdc.gov%2Fncchs%2Fahcd%2Fweb_tables.htm%2F232011&data=05%7C01%7CJessica.Avery%40smith-nephew.com%7C8ad0d87740af49a0dae308db5b07e4fd%7C273106dc287842ebb7c8069df334687%7C0%7C0%7C638203861705955737%7CUknown%7CTWFPbGzsb3d8eyJWJoiMC4wLjAwMDAilCJlQioiV2luMzIlCJBTi6Ik1haWwWILCJXVCi6Mn0%3D%7C3000%7C%7C%7C%7C&sdata=tEro56wHrxo9677yqSMLo9mVpX99qUBuBcdNSxqWwggw%3D&reserved=0)". 101. National Inpatient Sample (HCUP-NIS: 2010 data); National Hospital Discharge Survey (2010 data); recent 100% hospitalization data from several states. 102. National Fire Protection Association: Fire loss in the U.S. during 2014 (accessed on 2/8/16, at HYPERLINK "<https://nam11.safelinks.protection.outlook.com?url=http%3A%2F%2Fwww.nfpa.org%2Fresearch%2Freports-and-statistics%2Ffires-in-the-us-%2Foverall-fire-problem%2Ffire-loss-in-the-united-states&data=05%7C01%7CJessica.Avery%40smith-nephew.com%7C8ad0d87740af49a0dae308db5b07e4fd%7C273106dc287842ebb7c8069df334687%7C0%7C0%7C63820386170611191818%7CUnknown%7CTWFPbGzsb3d8eyJWJoiMC4wLjAwMDAilCJlQioiV2luMzIlCJBTi6Ik1haWwWILCJXVCi6Mn0%3D%7C3000%7C%7C%7C%7C&sdata=ZkQsIOe%2FjSlmDzISBMFPycoQLmjJw4peb9U4o85M4%3D&reserved=0>". 104. Herman, I. Stimulation of human keratinocyte migration and proliferation in vitro: insights into the cellular responses to wound and wound healing. Wounds. 1996; 8:33-40. 105. Riley et al. Collagenase promotes the cellular responses to injury and wound healing in vivo. J Burns Wounds. 2005; 4:112-124. 106. Shi L, Carson D. Collagenase Santyl ointment: a selective agent for wound debridement. J Wound Ostomy Continence Nurs. 2009;33(6 Suppl):S12-S16. doi:10.1097/WON.0b013e3181bfdd14. 107. Collagenase SANTYL Ointment [prescribing information]. Fort Worth, TX: Smith & Nephew, Inc.; 2016. 108. Shi et al. Degradation of human collagen isoforms by Clostridium collagenase and the effects of degradation products on cell migration. Int Wound J. 2010; 7: 87-95. 109. Frederick RE, Bearden R, Jovanovic A, Jacobson N, Sood R, Dhall S. Clostridium Collagenase Impact on Zone of Stasis Stabilization and Transition to Healthy Tissue in Burns. Int J Mol Sci. 2021; 22(16): 8643. Published 2021 Aug 11. doi:10.3390/ijms22168643. 110. Forni C, D'Alessandro F, Gallarani P, et al. Effectiveness of using a new polyurethane foam multi-layer dressing in the sacral area to prevent the onset of pressure ulcer in the elderly with hip fractures: A pragmatic randomised controlled trial. Int Wound J. 2018;15(3):383–390. 111. Salgado RM, Bravo L, García M, Melchor JM, Krötzsch E. Histomorphometric analysis of early epithelialization and dermal changes in mid partial-thickness burn wounds in humans treated with porcine small intestinal submucosa and silver-containing hydrofiber. J Burn Care Res. 2014;35(5):e330-e337. 112. Cuenca-Pardo J, Peralta-Comde D. Quemaduras en cara ratada con escision temprana y cubiertas con matriz acelular (Face burns treated with early excision and covered with an acellular matrix). Cir Plast. 2011;21(1):11-19. 113. Glik J, Kawecki M, Kitala D, et al. A new option for definitive burn wound closure – pair matching type of retrospective case-control study of hand burns in the hospitalised patients group in the Dr Stanislaw Sakiel Centre for Burn Treatment between 2009 and 2015. Int Wound J. 2017;14:849-855. 114. Haruang GD. The extracellular matrix in wound healing. Malvern, PA: HMP Communications; 2006:1-4. 115. MacNeil S. What role does the extracellular matrix serve in skin grafting and wound healing? Burns. 1994;20 Suppl 1:S67-S70. 116. Russell research reference, Russell Research RENASYS Messaging Study, Final Report, May 2022. Balcom Agency, USA. 117. Hurd T, Rossington A, Trueman P, Smith J. A retrospective comparison of the performance of two negative pressure wound therapy systems in the management of wounds of mixed etiology. Adv Wound Care. 2017;6(1):33-37. 118. Drifford, K; ACTICOAT Flex 3 has antimicrobial activity in 30 minutes, Data on file 0810018, Smith & Nephew. 119. Drifford, K; ACTICOAT Flex 7 has antimicrobial activity in 30 minutes, Data on file 0810014, Smith & Nephew. 120. Gago et al (2008) A comparison of Three Silver - containing Dressings in the Treatment of Infected, Chronic Wounds 20(10): 273-278. 121. Daubney, L: Silver Release Testing of ACTICOAT Flex 3 Dressings. Report reference DS/08/078/R2. 122. Drifford, K; Antimicrobial Activity of ACTICOAT Flex 3 against a Broad Spectrum of Wound Pathogens, Data on File reference 0810016. 123. Newton (2010) Reducing MRSA bacteraemia associated with wounds. Wounds uk, Vol 6, No 1. 124. Selcuk (2012) Comparison of the antibacterial effect of silver. Burns 38: 1204-1209. 125. Sibbald et al (2001) A screening evaluation of an ionised nanocrystalline silver dressing in chronic wound care. Ostomy Wound management 47(10), 38-4. 126. Chopra (2007) Increasing use of silver-based products. Jnl. Anti Chem. 127. Strohal, R, et al. Nanocrystalline silver dressings as an efficient anti-MRSA barrier: a new solution to an increasing problem. J. Hosp. Infect. 2006; 60, 226–30 (2005). 128. Upton, D. and Solowiej, K. (2010). Pain and Stress as Contributors to Delayed Wound Healing. Journal of The Australian Wound Management Association, 2010;18: 3-129. Gravante G, Palmieri MB, Esposito G, et al. Apoptotic death in deep partial thickness burns vs. normal skin of burned patients. J Surg Res. 2007;141(2):141-145. doi:10.1016/j.jss.2006.07.031. 130. Shupp JW, Nasabzadeh TJ, Rosenthal DS, Jordan MH, Fidler P, Jeng JC. A review of the local pathophysiologic bases of burn wound progression. J Burn Care Res. 2010;31(6):849-873. doi:10.1097/BCR.0b013e3181f93571. 131. Gravante G, Filingeri V, Delogu D, et al. Apoptotic cell death in deep partial thickness burns by coexpression analysis of TUNEL and Fas. Surgery. 2006;139(6):854-855. doi:10.1016/j.surg.2006.01.024. 132. Frederick RE, Bearden R, Jovanovic A, Jacobson N, Sood R, Dhall S. Int J Mol Sci. 2021;22(16):8643. Published 2021 Aug 11. doi:10.3390/ijms22168643.

**ACTICOAT<sup>o</sup>**

Order No	Size	Each/unit	Unit/case	HCPCS
20101	4" x 4"	12	4	A9270
20201	4" x 8"	12	4	A9270
20301	8" x 16"	6	4	A9270
20401	16" x 16"	6	2	A9270
20501	4" x 48"	6	2	A9270
20601	2" x 2"	5	20	A9270
20151	5" x 5"	5	5	A9270

**ACTICOAT<sup>o</sup>7**

Order No	Size	Each/unit	Unit/case	HCPCS
20341	2" x 2"	5	20	A9270
20141	4" x 5"	5	6	A9270
20241	6" x 6"	5	4	A9270

**ACTICOAT<sup>o</sup> Flex 3**

Order No	Size	Each/unit	Unit/case	HCPCS
66800402	2" x 2"	5	20	A6206
66800406	4" x 4"	12	4	A6207
66800417	4" x 8"	12	4	A6207
66800418	8" x 16"	6	4	A6208
66800433	16" x 16"	6	2	A6208
66800434	4" x 48"	6	2	A6208

**ACTICOAT<sup>o</sup> Flex 7**

Order No	Size	Each/unit	Unit/case	HCPCS
66800403	2" x 2"	5	20	A6206
66800405	4" x 5"	5	6	A6207
66800427	6" x 6"	5	4	A6207
66800407	8" x 16"	6	4	A6208
66800408	16" x 16"	6	2	A6208
66800544	1" x 24"	5	10	A6207

**ALLEVYN<sup>o</sup> Ag Adhesive**

Order No	Size	Each/unit	Unit/case	HCPCS
66020970	3" x 3"	10	4	A6212
66020973	5" x 5"	10	4	A6212
66020976	7" x 7"	10	4	A6213

**ALLEVYN<sup>o</sup> LIFE**

Order No	Size	Each/unit	Unit/case	HCPCS
66801067	4" x 4"	10	10	A6212
66801068	5" x 5"	10	5	A6213
66801069	6" x 5"	10	6	A6212
66801070	8" x 8"	10	4	A6213
66801304	Heel	5	6	A6213
66801306	Sacrum Small	10	6	A6212
66801307	Sacrum Large	10	4	A6213

**CICA-CARE<sup>o</sup> Adhesive Silicone Gel Sheet**

Order No	Size	Each/unit	Unit/case	HCPCS
66250707	5" x 7"	10	1	A6025

**CONFORMANT<sup>o</sup> 2 Wound Veil**

Order No	Size	Each/unit	Unit/case	HCPCS
5955044	4" x 4"	1	48	A6206
5955412	4" x 12"	1	48	A6207
59551212	12" x 12"	1	48	A6208
59551224	12" x 24"	1	48	A6208
59552436	24" x 36"	1	50	A6208
5955305	3" x 5yd	1	20	A6206 - A6208
5955602	6" x 2yd	1	20	A6206 - A6208

**CUTICERIN<sup>o</sup> Low-Adherent Surgical Dressing**

Order No	Size	Each/unit	Unit/case	HCPCS
66045562	3" x 3"	10	12	A6222
66045560	3" x 3"	50	6	A6222
66045564	4" x 4"	10	12	A6222
66045503	3" x 8" (3/pkg)	25	6	A6223
66045563	3" x 8"	10	12	A6223
66045561	3" x 8"	50	6	A6223
66045502	8" x 16"	25	6	A6224

**DURAMAX<sup>o</sup> S Silicone Super Absorbent Dressing**

Order No	Size	Each/unit	Unit/case	HCPCS
66023131	4" x 4"	10	40	A6196
66023132	6" x 8"	10	20	A6197
66023134	8" x 10"	10	16	A6198
66023135	8" x 16"	10	10	A6198



## EXU-DRY<sup>o</sup> Anti-Shear Wound Dressing

Order No	Size	Each/unit	Unit/case	HCPCS
5999M36	24" x 36" Pads/Sheets	1	15	A6253
5999M37	24" x 36" Pads/Sheets	1	24	A6253
5999L72	36" x 72" Pads/Sheets	1	15	A6253
5999L73	36" x 72" Pads/Sheets	1	15	A6253
5999L74	36" x 72" Pads/Sheets	1	15	A6253
5999LPA	Arm	1	20	A6253
5999LPG	Large Hand	1	20	A6253
5999MPG	Medium Hand	1	20	A6253
5999FM1	Adult Face	1	20	A6253
5999LPL	Leg	1	20	A6253
5999003S	3" Slit Disc (M) Wound Dressing	1	100	A6251
5999003	3" Disc Wound Dressing	1	100	A6251
5999034	3" x 4" Wound Dressing	1	100	A6251
5999004120	4" x 6" (F) Wound Dressing	1	120	A6252
5999006	6" x 9" (F) Wound Dressing	1	48	A6253
5999009	9" x 15" (F) Wound Dressing	1	30	A6253
5999018	15" x 18" (F) Wound Dressing	1	30	A6253
5999024	15" x 24" (F) Wound Dressing	1	30	A6253
5999028	20" x 28" (F) Wound Dressing	1	20	A6253
5999PTM	2" x 3" Slit Tube (F) Wound Dressing	1	50	A6251
5999034S	3" x 4" Slit Tube (F) Wound Dressing	1	50	A6252
5999101	4" x 6" Slit Tube (F) Wound Dressing	1	100	A6253
5999034	3" x 4" Wound Dressing	1	100	A6251
5999LJ1	Large Burn Torso Jacket	1	10	A6253
5999MJ1	Medium Burn Torso Jacket	1	10	A6253
5999LV1	Large Burn Vest	1	20	A6253
5999BP1	Adult Buttocks Vest	1	10	A6253

## INTRASITE<sup>o</sup> Gel Hydrogel Wound Dressing

Order No	Size	Each/unit	Unit/case	HCPCS
66027308	.28oz	10	4	A6248
66027311	.52oz	10	4	A6248
66027313	.88oz	10	4	A6248

## Collagenase SANTYL<sup>o</sup> Ointment 250 units/g

Order No	Size	Each/unit	Unit/case	HCPCS
50484-010-30	30gm tube	1	12	NDC: 50484-010-30
50484-010-90	90gm tube	1	12	NDC: 50484-010-90

## SOLOSITE<sup>o</sup> Wound Gel

Order No	Size	Each/unit	Unit/case	HCPCS
449600	3oz Tube	1	12	A6248

## PICO<sup>o</sup> 7 Single Use Negative Pressure Wound Therapy System

Order No	Size	Kits/case (2x dressing/kit)
66022002	10cm x 20cm	3
66022003	10cm x 30cm	3
66022004	10cm x 40cm	3
66022005	15cm x 15cm	3
66022006	15cm x 20cm	3
66022007	15cm x 30cm	3
66022008	20cm x 20cm	3
66022009	25cm x 25cm	3

Order No	Size	Kits/case (1x dressing/kit)
66022012	10cm x 20cm	3
66022013	10cm x 30cm	3
66022014	10cm x 40cm	3
66022015	15cm x 15cm	3
66022016	15cm x 20cm	3
66022017	15cm x 30cm	3
66022018	20cm x 20cm	3
66022019	25cm x 25cm	3

## PICO<sup>o</sup> 14 Single Use Negative Pressure Wound Therapy System

Order No	Size	Kits/case (2x dressing/kit)
66022042	10cm x 20cm	3
66022043	10cm x 30cm	3
66022044	10cm x 40cm	3
66022045	15cm x 15cm	3
66022046	15cm x 20cm	3
66022047	15cm x 30cm	3
66022048	20cm x 20cm	3
66022049	25cm x 25cm	3

## PICO<sup>o</sup> sNPWT Accessories

Order No	Size	Each/Unit	Unit/case	HCPCS
66801082	RENASYS Adhesive Gel Patch: 7cm x 10cm	5	10	A6223
66801692	Foam Wound Dressing: 10cm x 12.5cm x 1.5cm	1	5	-
66801691	Antimicrobial Gauze Dressing: 15cm x 17cm	5	10	-

## RENASYS<sup>o</sup> TOUCH Negative Pressure Wound Therapy System

Order No	Size	Each/unit	Unit/case
66802134	RENASYS TOUCH Pump	1	1
66801286	Power supply (Class 2)	1	1
66801564	Power cord (Class 2)	1	1
66801283	TOUCH O-ring	20	1
66801284	Odor filter	20	1
66021812	Service pack	1	10
66020971	Y-connector	1	1
66801278	RENASYS TOUCH IV/Bed pole clamp	1	1
66801273	300mL canister w/ solidifier	1	5
66801275	300mL canister w/out solidifier	1	5
66801274	800mL canister with solidifier	1	5
66801271	800mL canister w/out solidifier	1	5

## RENASYS<sup>o</sup> tNPWT Accessories

Order No	Size	Each/unit	Unit/case	HCPCS
66020794	RENASYS-F, Foam Dressing Kit with Soft Port, Small Kit	1	5	A6550
66020795	RENASYS-F, Foam Dressing Kit with Soft Port, Medium Kit	1	5	A6550
66020796	RENASYS-F, Foam Dressing Kit with Soft Port, Large Kit	1	5	A6550
66020797	RENASYS F, Foam Dressing Kit with Soft Port, X Large Kit	1	5	-
66027659	RENASYS WF, White Foam Small 7.5cm x 10cm x 1cm	10	6	-
66027660	RENASYS WF, White Foam Large 10cm x 15cm x 1cm	1	10	-
66021980	RENASYS-AB, Abdominal Dress- ing Kit with Soft Port	1	5	-
66801692	Foam Wound Dressing	1	5	-
66020933	RENASYS-G, Gauze Dressing Kit with Soft Port, Small Kit	1	5	A6550
66020934	RENASYS-G, Gauze Dressing Kit with Soft Port, Medium Kit	1	5	A6550
66020935	RENASYS-G, Gauze Dressing Kit with Soft Port, Large Kit	1	5	A6550
66801082	RENASYS Adhesive Gel Patch	10	5	-
66020799	RENASYS Soft Port	1	5	-
66800394	RENASYS Transparent Film (20cm x30cm)	10	10	-
66020853	RENASYS Transparent Film - X LARGE (38cm x 60 cm)	5	5	-
66800391	"NPWT Antimicrobial Large Gauze Roll"	1	10	-
66801691	Antimicrobial Gauze	1	10	A6223

## OASIS® Wound Matrix

Order No	Size	Sheets/box	HCPCS
8213-1000-33	3cm x 3.5cm (10.5cm <sup>2</sup> ) fenestrated	10	Q4102
8213-1000-37	3cm x 7cm (21cm <sup>2</sup> ) fenestrated	10	Q4102

## OASIS® Burn Matrix

Order No	Size	Sheets/box	HCPCS
8213-3000-16	3cm x 3.5cm (10.5cm <sup>2</sup> ) fenestrated	5	Q4103
8213-3000-18	3cm x 7cm (21cm <sup>2</sup> ) fenestrated	5	Q4103
8213-3000-13	5cm x 7cm (35cm <sup>2</sup> ) meshed	5	Q4103
8213-3000-09	7cm x 10cm (70cm <sup>2</sup> ) meshed	5	Q4103
8213-3000-11	7cm x 20cm (140cm <sup>2</sup> ) meshed	5	Q4103

## OASIS® XL Matrix

Order No	Size	Sheets/box	HCPCS
8213-3000-20	20cm x 30cm (600cm <sup>2</sup> ), perforated	1	-

## OASIS® ULTRA Tri-Layer Matrix

Order No	Size	Sheets /box	HCPCS
8213-0000-16	3cm x 3.5cm (10.5cm <sup>2</sup> ) fenestrated	5	Q4124
8213-0000-18	3cm x 7cm (21cm <sup>2</sup> ) fenestrated	5	Q4124
8213-0000-13	5cm x 7cm (35cm <sup>2</sup> ) meshed	5	Q4124
8213-0000-09	7cm x 10cm (70cm <sup>2</sup> ) meshed	5	Q4124
8213-0000-11	7cm x 20cm (140cm <sup>2</sup> ) meshed	5	Q4124

## OASIS® MICRO Micronized Wound Matrix

Order No	Size	Bottles/box	HCPCS
C-ECM-PWD-200MG	200mg (covers approx. 35cm <sup>2</sup> )	1	-
C-ECM-PWD-500MG	500 mg (covers approx. 85cm <sup>2</sup> )	1	-
C-ECM-PWD-1000MG	1000mg (covers approx. 170cm <sup>2</sup> )	1	-

## VERSAJET® II Hydrosurgery System

Order No	Size	Each/unit	Unit/case
66800039	Console (includes user manual, power cord and multi-function footswitch)	1	1
66800484	Console user manual	1	1
66800472	Replacement multi-function footswitch	1	1
66800193	Replacement power cord	1	1
66800979	VERSAJET II cart	1	1
66800475	Replacement shelf	1	1
66800041	VERSAJET II EXACT 45°/14mm	1	5
66800042	VERSAJET II EXACT 45°/8mm	1	5
66800040	VERSAJET II EXACT 15°/14mm	1	5
66800044	VERSAJET II PLUS 45°/14mm	1	5
66800045	VERSAJET II PLUS 45°/8mm	1	5
66800043	VERSAJET II PLUS 15°/14mm	1	5



is of the essence

For detailed product information, including indications for use, contraindications, precautions and warnings, please consult each product's Instructions for Use (IFU) prior to use.

Advanced Wound Management  
Smith & Nephew, Inc.  
Fort Worth, TX 76109  
USA

[www.smith-nephew.com](http://www.smith-nephew.com)  
Customer Care Center:  
1 800 876-1261  
T 727 392-1261  
F 727 392-6914

©2023 Smith & Nephew, Inc.  
®Trademark of Smith & Nephew  
TMAll trademarks acknowledged. OASIS is  
a registered trademark of Cook Biotech, Inc.  
MSPE10-38459-0823

Supporting healthcare professionals for over 150 years